Impact of previous DMT on effectiveness, safety outcomes in PwMS treated w/Lemtrada on: April 05, 2021, 03:17:30 pm #1 From the Journal of Neurology, Neurosurgery and Psychiatry (April 5, 2021), "Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab":https://jnnp.bmj.com/content/early/2021/03/11/jnnp-2020-325304.longA summary of the findings is in Multiple Sclerosis News Today (April 5)--"Moving from Gilenya to Lemtrada May Not Be Optimal Choice, Study Says": Moving From Gilenya to Lemtrada May Not Be Optimal Choice in RRMS Compared with other DMTs, use of oral Gilenya before Lemtrada associated with a greater likelihood of relapses and disease worsening in study. Multiple Sclerosis News Today · multiplesclerosisnewstoday.com Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
